Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
The purpose of the study CTQJ230A12304, is to evaluate the efficacy, safety, and tolerability of pelacarsen (TQJ230) compared to placebo in participants with ASCVD who have elevated Lipoprotein A (Lp(a)), and who are on background inclisiran treatment for elevated Lipoprotein associated cholesterol (LDL-C).
Epistemonikos ID: e73ce26a75b2c16efe870b28183111003bf11924
First added on: Mar 01, 2025